Finally, only a 99mTc-labeled PSMA can be employed for radioguided surgery in prostate cancer, and our Nuclear Medicine service has successfully demonstrated the proof-of-concept of this new radiopharmaceutical. This evidence concerns the gene FOLH1 and prostate cancer.